Interim Research Products

HEALTH RESEARCH ALLIANCE
MEMBERS’ MEETING
September 27, 2016

Neil Thakur, PhD
National Institutes of Health
Where we are

• Potential to advance science
  • No standard definitions or rules
  • Implications for review are unclear

• We are asking the community for advice
What are interim research products?  
(working definitions)

*Complete, public research products that are not final*

This is a very broad definition. We do not intend to focus on research products specifically addressed in other policies, such as data, clinical trials, physical collections, etc.

Intended examples and current focus

**Preprints** are complete and public drafts of a scientific documents. Speeds dissemination, establishes priority, generates feedback, may reduce publication bias.

**Preregistering** protocols is publicly declaring key elements of a research project in advance, such as hypotheses, measures, confirmatory research protocols and analysis plans. May reduce biases like p-hacking.
Why now?
A dynamic situation with the potential to advance science

• Growing recognition that interim research products could speed the dissemination of science and enhance rigor
  ▪ Many disciplines have been using preprints for years (economics, physics)
  ▪ Groups like ASAPbio suggest expand preprints could increase the impact of NIH research
  ▪ Groups like the Center for Open Science suggest preregistration could enhance rigor of NIH supported research

• Change happening at different rates for different disciplines

• No clear definitions

• NIH rules are narrow
NIH’s interest:  
Stable rules that advance science

Recognize common practices and encourage beneficial innovation
  • Allow disciplines to adopt interim research products at their own pace (and recognize that many already do)
  • Do not prevent innovation that increases rigor and dissemination

Prevent bad practices from taking root
  Clearly state standards NIH cannot accept as community norms are being established
    ▪ Interim products that are not preserved, risk NIH reviewer identity, etc, are not usable
    ▪ Example: a file on a lab webpage is not an acceptable preprint.
Next Step: An RFI on interim research products

1. Feedback on what is considered to be interim research products, and how they are used.
2. Insight on how particular types of interim research products might impact the advancement of science.
3. Feedback on potential citation standards.
4. Insight on the need and potential impact of citing interim products on peer review for NIH applications.
5. Advice on how NIH reviewers might evaluate citations of interim research products in applications.
Implementation details under consideration:
Possible standards for citing interim research products

• Registered or indexed (findable)

• persistent identifier, that links to a repository that will maintain the privacy of the end user

• Uses the CC-BY license. Readable by both human and machine

• Includes a record of modifications, and a link to the final version

• Declares any competing interests

• Policy statement clarifying scope: “does not apply to research products specifically addressed in other policies, such as data (URL), clinical trials (URL), physical collections (URL), etc.”
Implementation details under consideration: Possible standards specifically for preprints

• a clear statement in the document that the information is preliminary (understandable to non-experts)

• concordance with standard practices for scholarly publication, including:
  ▪ following norms for authorship in that discipline;
  ▪ including or linking to supplemental data;
  ▪ providing appropriate funding acknowledgments;
  ▪ conforming to applicable regulations and ethical standards, including those regarding human participants, animal welfare, and dual use technology.
Discussion and feedback
Selected reading

For more information about preprints

For more information about preregistration
• https://osf.io/peut2/?_ga=1.256408971.1617774245.1468588454
• https://wiki.galaxyproject.org/FrontPage